Document is current
Any future updates will be listed below
-
Authors
Li, Huiping
Huang, Yan
Chen, Zhendong
Zeng, Aiping
Zhang, Helong
Yu, Yan
Wei, Shihong
Li, Qingshan
Wang, Xiaojia
Wang, Xiangcai
Wang, Xiuwen
Yang, Runxiang
Dai, Xiumei
Bi, Minghong
Sun, Tao
Zhang, Qingyuan
Han, Cuicui
Li, Yujie
Kang, Xiaoyan
Liu, Yaxin
Zhang, Li
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04550949 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
https://doi.org/10.1007/s40259-023-00579-5
-
Funding
Funding for this research was provided by:
Qilu Pharmaceutical Co., Ltd.
- License Information
-
More Information
Article History
Accepted: 11 January 2023
First Online: 21 February 2023
Declarations
:
: This study was funded by Qilu Pharmaceutical Co., Ltd.
: Cuicui Han, Yunjie Li, and Xiaoyan Kang are employees of Qilu Pharmaceutical Co., Ltd. All the other authors have no conflicts of interest that are directly relevant to the content of this article.
: The study protocol was approved by the ethics committee in each center.
: All patients provided written informed consent before participation.
: Not applicable.
: The datasets generated during and/or analyzed during the current study are not publicly available because we may further analyze the raw data for other research objectives.
: Not applicable.
: HL and LZ had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: HL, YH, CH, XK, LZ. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: HL, YH, LZ. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: YL. Obtained funding: HL, XK, LZ. Administrative, technical, or material support: CH, XK. Supervision: HL, XK, LZ.
